Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-18-005111.pdf
0001558370-18-005111.rtf
0001558370-18-005111.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000899243-18-012782.pdf
0000899243-18-012782.rtf
0000899243-18-012782.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000899243-18-012543.pdf
0000899243-18-012543.rtf
0000899243-18-012543.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-18-006475.pdf
0001179110-18-006475.rtf
0001179110-18-006475.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0000899243-18-011871.pdf
0000899243-18-011871.rtf
0000899243-18-011871.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-18-003702.pdf
0001558370-18-003702.rtf
0001558370-18-003702.xls
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-18-003771.pdf
0001558370-18-003771.rtf
0001558370-18-003771.xls
EX-101.INS - EX-101.INS
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

 View HTML
0001558370-18-003430.pdf
0001558370-18-003430.rtf
0001558370-18-003430.xls
DEFA14A

Additional proxy soliciting materials - definitive

 View HTML
0001558370-18-003433.pdf
0001558370-18-003433.rtf
0001558370-18-003433.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001558370-18-002987.pdf
0001558370-18-002987.rtf
0001558370-18-002987.xls